Limits...
Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer.

Wallin U, Glimelius B, Jirström K, Darmanis S, Nong RY, Pontén F, Johansson C, Påhlman L, Birgisson H - Br. J. Cancer (2011)

Bottom Line: Patients with CRC with moderate to high intensity of GDF15 immunostaining had a higher recurrence rate compared with patients with no or low intensity in all stages (stages I-III) (HR, 3.9; 95% CI, 1.16-13.15) and in stage III (HR, 10.32; 95% CI, 1.15-92.51).Patients with high plasma levels of GDF15 had statistically shorter time to recurrence (P=0.041) and reduced overall survival (P=0.002).High expression of GDF15 in tumour tissue and high plasma levels correlate with an increased risk of recurrence and reduced overall survival.

View Article: PubMed Central - PubMed

Affiliation: Division of Colon and Rectal Surgery, Department of Surgery, University of Minnesota, 2800 Medical Building, 2800 Chicago Avenue South, Suite 300, Minneapolis, MN, USA. ulrik.wallin@surgsci.uu.se

ABSTRACT

Background: Growth differentiation factor 15 (GDF15) belongs to the transforming growth factor beta superfamily and has been associated with activation of the p53 pathway in human cancer. The aim of this study was to assess the prognostic value of GDF15 in patients with colorectal cancer (CRC).

Methods: Immunohistochemistry and tissue microarrays were used to analyse GDF15 protein expression in 320 patients with CRC. In a subgroup of 60 patients, the level of GDF15 protein in plasma was also measured using a solid-phase proximity ligation assay.

Results: Patients with CRC with moderate to high intensity of GDF15 immunostaining had a higher recurrence rate compared with patients with no or low intensity in all stages (stages I-III) (HR, 3.9; 95% CI, 1.16-13.15) and in stage III (HR, 10.32; 95% CI, 1.15-92.51). Patients with high plasma levels of GDF15 had statistically shorter time to recurrence (P=0.041) and reduced overall survival (P=0.002).

Conclusion: Growth differentiation factor 15 serves as a negative prognostic marker in CRC. High expression of GDF15 in tumour tissue and high plasma levels correlate with an increased risk of recurrence and reduced overall survival.

Show MeSH

Related in: MedlinePlus

Mean preoperative plasma levels of GDF15 and CEA in patients with colorectal cancer stages I–IV (n=57).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3101900&req=5

fig5: Mean preoperative plasma levels of GDF15 and CEA in patients with colorectal cancer stages I–IV (n=57).

Mentions: The GDF15 plasma levels gradually increased with disease stage, whereas the CEA levels were low in stages I–III and markedly increased in stage IV (Figure 5). There was a weak correlation between the GDF15 plasma levels and CEA in the whole cohort (P<0.001; r=0.49), however, a stronger correlation was observed in stage IV (P=0.045; r=0.72).


Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer.

Wallin U, Glimelius B, Jirström K, Darmanis S, Nong RY, Pontén F, Johansson C, Påhlman L, Birgisson H - Br. J. Cancer (2011)

Mean preoperative plasma levels of GDF15 and CEA in patients with colorectal cancer stages I–IV (n=57).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3101900&req=5

fig5: Mean preoperative plasma levels of GDF15 and CEA in patients with colorectal cancer stages I–IV (n=57).
Mentions: The GDF15 plasma levels gradually increased with disease stage, whereas the CEA levels were low in stages I–III and markedly increased in stage IV (Figure 5). There was a weak correlation between the GDF15 plasma levels and CEA in the whole cohort (P<0.001; r=0.49), however, a stronger correlation was observed in stage IV (P=0.045; r=0.72).

Bottom Line: Patients with CRC with moderate to high intensity of GDF15 immunostaining had a higher recurrence rate compared with patients with no or low intensity in all stages (stages I-III) (HR, 3.9; 95% CI, 1.16-13.15) and in stage III (HR, 10.32; 95% CI, 1.15-92.51).Patients with high plasma levels of GDF15 had statistically shorter time to recurrence (P=0.041) and reduced overall survival (P=0.002).High expression of GDF15 in tumour tissue and high plasma levels correlate with an increased risk of recurrence and reduced overall survival.

View Article: PubMed Central - PubMed

Affiliation: Division of Colon and Rectal Surgery, Department of Surgery, University of Minnesota, 2800 Medical Building, 2800 Chicago Avenue South, Suite 300, Minneapolis, MN, USA. ulrik.wallin@surgsci.uu.se

ABSTRACT

Background: Growth differentiation factor 15 (GDF15) belongs to the transforming growth factor beta superfamily and has been associated with activation of the p53 pathway in human cancer. The aim of this study was to assess the prognostic value of GDF15 in patients with colorectal cancer (CRC).

Methods: Immunohistochemistry and tissue microarrays were used to analyse GDF15 protein expression in 320 patients with CRC. In a subgroup of 60 patients, the level of GDF15 protein in plasma was also measured using a solid-phase proximity ligation assay.

Results: Patients with CRC with moderate to high intensity of GDF15 immunostaining had a higher recurrence rate compared with patients with no or low intensity in all stages (stages I-III) (HR, 3.9; 95% CI, 1.16-13.15) and in stage III (HR, 10.32; 95% CI, 1.15-92.51). Patients with high plasma levels of GDF15 had statistically shorter time to recurrence (P=0.041) and reduced overall survival (P=0.002).

Conclusion: Growth differentiation factor 15 serves as a negative prognostic marker in CRC. High expression of GDF15 in tumour tissue and high plasma levels correlate with an increased risk of recurrence and reduced overall survival.

Show MeSH
Related in: MedlinePlus